Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$36.06
+2.0%
$31.92
$23.42
$62.58
$2.09B0.73653,612 shs258,713 shs
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
$25.59
$25.59
$9.90
$25.61
$2.21B0.191.29 million shs600 shs
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$6.16
+3.4%
$6.17
$5.51
$12.65
$1.88B0.513.17 million shs3.12 million shs
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$20.96
$22.66
$16.60
$28.47
$1.55B1.58914,852 shs348,387 shs
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$42.97
$42.83
$32.67
$45.76
$1.62B0.5645,199 shsN/A
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
0.00%+7.72%+5.95%+39.97%-14.20%
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
0.00%+3.79%+0.90%-17.93%-37.26%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
0.00%+1.70%-11.67%+16.25%+4.28%
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
4.0976 of 5 stars
3.41.00.04.31.90.81.9
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
3.7085 of 5 stars
3.41.00.04.30.60.01.9
Schrodinger, Inc. stock logo
SDGR
Schrodinger
2.7965 of 5 stars
3.42.00.00.02.92.50.6
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
2.71
Moderate Buy$58.6062.53% Upside
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
0.00
N/AN/AN/A
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
2.70
Moderate Buy$16.22163.56% Upside
Schrodinger, Inc. stock logo
SDGR
Schrodinger
2.75
Moderate Buy$33.2558.64% Upside
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SDGR, AGIO, FOLD, DCPH, and TARO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/3/2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight$28.00
5/2/2025
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$74.00 ➝ $71.00
5/2/2025
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.00 ➝ $22.00
5/2/2025
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$12.00 ➝ $9.00
4/16/2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$30.00 ➝ $32.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$36.50M57.21N/AN/A$27.02 per share1.33
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
$174.91M12.65N/AN/A$4.38 per share5.84
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$528.29M3.59N/AN/A$0.65 per share9.47
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$207.54M7.41N/AN/A$5.78 per share3.63
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$629.18M2.57$2.38 per share18.03$47.70 per share0.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$673.72M$11.243.21N/AN/A1,798.26%-2.75%-2.52%7/30/2025 (Estimated)
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
-$194.94M-$2.21N/AN/AN/A-108.86%-52.42%-40.05%N/A
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
-$56.11M-$0.09N/A14.31N/A-5.41%4.67%1.05%8/14/2025 (Estimated)
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$187.12M-$2.63N/AN/AN/A-83.39%-44.74%-26.29%7/30/2025 (Estimated)
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$53.87M$1.4429.84N/A8.56%3.75%3.09%N/A

Latest SDGR, AGIO, FOLD, DCPH, and TARO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$0.83N/AN/AN/A$52.03 millionN/A
5/7/2025Q1 2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million
5/1/2025Q1 2025
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/AN/AN/AN/AN/A
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
N/AN/AN/AN/AN/A
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
N/AN/AN/AN/AN/A
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/AN/AN/AN/AN/A
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
18.50
17.93
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
N/A
4.19
3.94
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
2.02
3.34
2.47
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/A
3.45
3.45
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/A
3.61
3.04
CompanyEmployeesShares OutstandingFree FloatOptionable
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
39057.92 million55.43 millionOptionable
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
30086.48 million82.44 millionOptionable
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
480307.93 million301.16 millionOptionable
Schrodinger, Inc. stock logo
SDGR
Schrodinger
79073.38 million67.07 millionOptionable
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
1,55437.59 million32.40 millionOptionable

Recent News About These Companies

FDA approves first generics of anticoagulant Xarelto
Taro to acquire 100% stake in Antibe Therapeutics
Sun Pharma unit poised to buy Canadian biotech Antibe

New MarketBeat Followers Over Time

Media Sentiment Over Time

Agios Pharmaceuticals stock logo

Agios Pharmaceuticals NASDAQ:AGIO

$36.06 +0.71 (+1.99%)
Closing price 07/3/2025 01:04 PM Eastern
Extended Trading
$36.06 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Deciphera Pharmaceuticals stock logo

Deciphera Pharmaceuticals NASDAQ:DCPH

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Amicus Therapeutics stock logo

Amicus Therapeutics NASDAQ:FOLD

$6.16 +0.21 (+3.45%)
Closing price 07/3/2025 03:39 PM Eastern
Extended Trading
$6.08 -0.08 (-1.22%)
As of 07/3/2025 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Schrodinger stock logo

Schrodinger NASDAQ:SDGR

$20.96 0.00 (0.00%)
Closing price 07/3/2025 03:29 PM Eastern
Extended Trading
$21.04 +0.08 (+0.38%)
As of 07/3/2025 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Taro Pharmaceutical Industries stock logo

Taro Pharmaceutical Industries NYSE:TARO

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.